solute carrier family 4 member 5Genealiases: NBC4 · NBCe2
Q-omics provides the consensus-scored SLC4A5 profile across patient tissues and cancer cell-line models. SLC4A5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC4A5 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, SLC4A5 RNA expression shows 19,188 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUSC, and UVM as cancer lineages where SLC4A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC4A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC4A5 survival associations across molecular data types. SLC4A5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC4A5 RNA expression–survival associations across cancer types. High SLC4A5 expression shows unfavorable associations in KIRC, KIRP and UCEC, but favorable associations in UCS, LUAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC4A5 RNA expression.
This table summarizes SLC4A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC4A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC4A5 shows lower tumor expression in LUSC, LUAD and THCA and higher tumor expression in KICH, LIHC and HNSC. The LUSC box plot shows higher SLC4A5 RNA expression in normal versus tumor tissue (log2 FC = −0.658, t-test p < 0.001).
This table shows molecular features associated with SLC4A5 in patient tissues and cancer cell lines. In patient samples, SLC4A5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC4A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
